Aligos Therapeutics, Inc. (ALGS)
2.15
-0.42
(-16.34%)
USD |
NASDAQ |
Nov 11, 16:00
2.09
-0.06
(-2.79%)
After-Hours: 19:59
Aligos Therapeutics Shareholders Equity (Quarterly) : 11.31M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 11.31M |
| June 30, 2026 | 31.88M |
| March 31, 2026 | 31.79M |
| December 31, 2025 | 53.54M |
| September 30, 2025 | 71.83M |
| June 30, 2025 | 101.87M |
| March 31, 2025 | 116.44M |
| December 31, 2024 | -28.97M |
| September 30, 2024 | 50.10M |
| June 30, 2024 | 67.23M |
| March 31, 2024 | 59.80M |
| December 31, 2023 | 92.08M |
| September 30, 2023 | 54.82M |
| Date | Value |
|---|---|
| June 30, 2023 | 69.64M |
| March 31, 2023 | 84.75M |
| December 31, 2022 | 103.90M |
| September 30, 2022 | 122.01M |
| June 30, 2022 | 136.98M |
| March 31, 2022 | 152.89M |
| December 31, 2021 | 184.73M |
| September 30, 2021 | 217.01M |
| June 30, 2021 | 168.88M |
| March 31, 2021 | 195.22M |
| December 31, 2020 | 220.04M |
| September 30, 2020 | -136.67M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Anika Therapeutics, Inc. | 137.58M |
| BioCryst Pharmaceuticals, Inc. | -397.38M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 47.19M |
| Total Liabilities (Quarterly) | 35.88M |
| Debt to Equity Ratio | 1.052 |
| Current Ratio | 1.770 |
| Net Debt Paydown Yield | -2.86% |